Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort
Franck E. Nicolini(Hôpital Edouard Herriot), Delphine Réa(Institut Bergonié), Madeleine Etienne(Hôpital Lyon Sud), Stéphane Morisset(Lyon 1 Université), Yann Guillermin(Hôpital de la Croix-Rousse), Fiorenza Barraco(Hôpital Lyon Sud), Emilie Blond(Centre de Recherche en Nutrition Humaine Rhône-Alpes), Celine Fettig(Hôpital Edouard Herriot), Jérémy Ruby(Hôpital Lyon Sud), Laurence Legros(Hôpital l'Archet), Mauricette Michallet(Université Claude Bernard Lyon 1), Oriane Le Borgne(Hôpital Lyon Sud), Mohamad Sobh(Ottawa Hospital), Marie‐Claude Gagnieu(Hôpital Edouard Herriot), G. Richard-Colmant(Hôpital de la Croix-Rousse), Maël Heiblig(Université Claude Bernard Lyon 1)
Cited by 27
Related Papers
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414